Samumed is developing drugs for multiple degenerative diseases, including osteoarthritis, alopecia (baldness), and degenerative disc disease. While these therapies differ from each other, they all focus on restoring the Wnt signaling pathway.
The Wnt pathway is fundamental in stem cell differentiation. It allows for ordinary tissue repair and upkeep, and it provides for wound healing and recovery from injuries. However, like many other pathways, it becomes deregulated with age. By restoring this pathway, Samumed intends to replenish deteriorating tissues with the body’s own cells, staving off age-related diseases.
Samumed is currently in human trials with its lead candidate drug lorecivivint for the treatment of knee osteoarthritis.